Prefilled Syringe Drug Molecule Market to Reach USD 125,678 million by 2034 at a 6% of CAGR

Prefilled Syringes Drug Molecules Market
Prefilled Syringes Drug Molecules Market

The prefilled syringe drug molecule market is set for significant expansion, with projected sales increasing from USD 70,177.9 million in 2024 to USD 125,678 million by 2034, reflecting a compound annual growth rate (CAGR) of 6% during this period.

Prefilled Syringe Drug Molecule Market Dynamics

The increasing need for biologics is presumed to drive the demand for prefilled syringe drug molecules in the current period. By providing a more precise and controlled drug delivery system for biologics, prefilled syringe drug molecules are primarily accepted among patients. Moreover, the surge in the prevalence of chronic diseases has driven up demand for the industry in recent years.

As a requirement for frequent injections among patients who suffer from chronic illness, medical professionals are increasingly using prefilled syringes drug molecules owing to their benefits. These syringe drug molecules provide a painless and more convenient option for patients.

Self-administered drugs have gained popularity over the years, contributing to the sector’s demand nowadays. As people seek out self-controlling healthcare therapies, prefilled syringe drug molecules are increasingly providing easy-to-use options for these individuals to achieve maximum industry potential.

The ever-changing regulatory environment is likely to hinder industry growth during the forecast horizon. Also, these regulatory changes create significant industry barriers for manufacturers as they must be up to date with the latest regulations and ensure their product’s quality standards according to them.

Prefilled syringes have high manufacturing costs, which can limit sector growth in the coming years. Additionally, these high-cost obstacles can impact product pricing and competitiveness in the industry. Sterilization is another challenging factor for the sector’s growth. Manufacturers need to pay attention to quality standards and ensure that the syringe is strong enough.

Growth Drivers

  • Self-Administration: The rising trend of self-administration of medications is a major driver for the market, as prefilled syringes facilitate easier and safer drug delivery at home.
  • Demand for Biological Drugs: There is an increasing demand for biological drugs that often require precise dosing and minimal contamination risk, both of which are advantages offered by prefilled syringes.
  • User Benefits: Prefilled syringes provide several advantages, including ease of use, accurate dosing, reduced contamination risk, and improved patient compliance.

Regional Insights

  • The North American market is expected to lead due to high healthcare spending and a strong preference for self-injection devices.
  • The Asia-Pacific region is anticipated to witness rapid growth driven by increasing healthcare access and rising awareness of biologics.

Competitive Landscape

The prefilled syringe drug molecule market is also highly competitive. Leading firms are continuously investing in research and development activities to capture substantial industry share in the coming years. Several smaller players are entering the industry and making excellent contributions to this industry.

Recent Development

  • In 2023, Schott Pharma introduced prefilled polymer syringes specifically designed for deep-cold drugs. The company’s latest innovation aims to provide a safe and efficient delivery system for medications that require storage at extremely low temperatures, such as COVID-19 vaccines. These prefilled syringes are made of a special type of polymer material that can withstand freezing and thawing effects, ensuring the integrity of the drug inside. The new syringes are expected to streamline the administration process of deep-cold drugs and offer healthcare providers more options for efficient and reliable patient care.
  • In 2024, Hikma Pharmaceuticals announced the launch of Fentanyl Citrate Injection, USP, in a prefilled syringe in the United States. The drug is indicated for managing pain in opioid-tolerant patients, typically those with cancer pain. This prefilled syringe provides a convenient and easy-to-use option for healthcare providers to administer the medication. Fentanyl Citrate Injection, USP, is a potent opioid analgesic, and its use requires careful patient selection, dosing, and monitoring to reduce the risk of addiction, abuse, and misuse.

Key Companies Profiled

Amgen Inc.; Teva Pharmaceutical Industries Ltd.; AstraZeneca plc; Mylan N.V.; Pfizer, Inc.; Fresenius Kabi AG; Johnson & Johnson; Sanofi; Merck & Co. Inc.; Novartis AG; McKesson Corporation

Full Report Revealed

Key Segments

By Drug Class:

Depending on the drug class, the industry is categorized into vaccines, insulin, adrenaline, opioids, and others.

By Application Type:

Prefilled syringe drug molecules are effective in cardiovascular diseases, diabetes, immunization, and pain management.

By End User:

Key end-user industries are hospital pharmacies, retail pharmacies, online pharmacies, and drug stores.

By Region:

Regional analysis of the industry is conducted in North America, Latin America, Europe, South Asia, East Asia, Oceania, and the Middle East and Africa.

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogs | YouTube

About the Author

Nikhil Kaitwade

Associate Vice President at Future Market Insights, Inc. has over a decade of experience in market research and business consulting. He has successfully delivered 1500+ client assignments, predominantly in Automotive, Chemicals, Industrial Equipment, Oil & Gas, and Service industries.
His core competency circles around developing research methodology, creating a unique analysis framework, statistical data models for pricing analysis, competition mapping, and market feasibility analysis. His expertise also extends wide and beyond analysis, advising clients on identifying growth potential in established and niche market segments, investment/divestment decisions, and market entry decision-making.
Nikhil holds an MBA degree in Marketing and IT and a Graduate in Mechanical Engineering. Nikhil has authored several publications and quoted in journals like EMS Now, EPR Magazine, and EE Times.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may also like these